Evido processed 1M test results using LiverPRO in 2026
The tool uses routine blood test parameters and adjusts automatically for missing values to detect steatotic liver disease early.
See the latest news and media coverage for Evido. We track all announcements, press releases, and industry mentions in real time, all in one place.
Healthcare software company for early liver fibrosis detection
evido.healthLast updated
In short: Evido partnered with Roche, validated LiverPRO's clinical performance, and expanded leadership during 2025-2026.
The tool uses routine blood test parameters and adjusts automatically for missing values to detect steatotic liver disease early.
In a study of 5,695 individuals, LiverPRO and ADAPT achieved 82% sensitivity and 81% specificity, outperforming FIB-4.
The LiverPRO tech will be accessible to physicians and patients through Roche's navify Algorithm Suite, enabling affordable, non-invasive liver fibrosis testing during routine consultations worldwide.
They will distribute Evido's CE-certified LiverPRO through Roche's navify Algorithm Suite to enable non-invasive liver fibrosis detection during routine consultations.
As a result, the Danish health tech startup Evido has developed an AI-powered algorithm called LiverPRO which can assess a patient’s risk of liver fibrosis...
After leaving Coloplast in May, Villumsen has embarked on a career as a board member and investor.
Evido Health gains muscle partnering with Roche to more effectively sell its software solution for early detection of chronic liver disease,...
The company has developed software that uses artificial intelligence (AI) to detect liver diseases based on so-called biomarkers in patient blood samples.
Track Evido and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.